Microsoft Corporation (NASDAQ: MSFT) beats adjusted Non-GAAP EPS consensus of approx. USD 4.21 in Q4-FY2026 earnings (29 July 2026, after market close, confirmed by Microsoft press release)
Pending
✦ AI-generated prediction
Published on 26. July 2026
·
Predicted for 29. July 2026
·
Based on: Statistical Pattern
Analyst consensus for Microsoft's Q4 FY2026 stands at USD 4.21–4.24 Non-GAAP EPS (+15.3% YoY). Microsoft has beaten estimates in four consecutive quarters. Azure growth expected above 33% (separate platform prediction), with Copilot Enterprise and GitHub subscriptions adding upside. No direct Polymarket data; historical beat track and sector momentum (Intel Q2 2026 beat by 100%, Amazon expectations also elevated) imply >80% hit probability.
Data basis for this prediction
- IG International: Microsoft Q4 FY2026 Earnings Preview – EPS-Konsens $4.21–$4.24, 21. Juli 2026
- Yahoo Finance: MSFT Q4 FY2026 – Wachstum 15,3% YoY, 4 konsekutive EPS-Beats, Stand Juli 2026
- 247wallst.com: Intel Q2 2026 Earnings – $0.42 vs. $0.21 Konsens (+100% Beat), 23. Juli 2026
- alphastreet.com: Tech-Sektor Q2/Q4-2026 Earnings Beat-Raten, Stand Juli 2026
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
📈 Economy
✦ AI
Palantir has beaten the Non-GAAP EPS consensus for eight consecutive quarters. Q2 2026 consensus stands at ~USD 0.34 per share (vs. USD 0.16 in Q2 2025, +113% YoY), driven by US government contracts (Army AIP, SAS expansion) and strongly growing US commercial segment (AIP Enterprise deployments). Note: the separate long-term platform prediction (stock decline >45% by year-end) relates to valuation, not short-term earnings performance – no contradiction. Tipranks/Polymarket historical beat track for PLTR: >85%.
📈 Economy
✦ AI
The ECB plans a rate hike to 2.50% in September 2026 (separate platform prediction), indicating persistent inflation above the 2.0% target. Brent crude currently at ~USD 97/bbl (+34% since early July 2026 due to Middle East tensions), acting as energy price driver for the July CPI. EUR/USD at 1.1367 (24 July 2026) – moderate imported inflation. No direct Polymarket data; author estimate: 65% for annual rate ≥2.3%. Risk: base effects could accelerate disinflation.
📈 Economy
✦ AI
AstraZeneca has consistently beaten consensus expectations over the past six semi-annual and quarterly results, driven by oncology blockbusters (Tagrisso, Enhertu, Imfinzi) and the rare disease portfolio (Ultomiris, Soliris). FY2026 Core EPS growth of ≥10% YoY is company guidance. H1 2026 boosted by Farxiga launches in new indications and emerging market growth. No direct Polymarket data; historical beat probability >70% for AZ. Risks: FX pressure USD/GBP, generic competition for Tagrisso.